Use of generic alendronate in the treatment of osteoporosis

South African Medical Journal

Volumn 96, Issue 8, 2006, Pages 696-697

  Hough, Stephen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GENERIC DRUG; RISEDRONIC ACID;

ACCURACY; ACUTE PHASE RESPONSE; ARTICLE; ASIA; AVASCULAR NECROSIS; BEVERAGE; BIOEQUIVALENCE; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CLINICAL PRACTICE; CLINICAL TRIAL; COST CONTROL; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG INFORMATION; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG URINE LEVEL; EPIGASTRIC PAIN; ESOPHAGITIS; ESOPHAGUS INJURY; FOOD DRUG INTERACTION; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; HYPOCALCEMIA; INTESTINE ABSORPTION; KIDNEY DYSFUNCTION; MEDICAL INFORMATION; MEDICAL RESEARCH; NAUSEA AND VOMITING; NONHUMAN; OSTEOPOROSIS; PATIENT SAFETY; QUANTITATIVE ANALYSIS; SOUTH AFRICA; SOUTH AND CENTRAL AMERICA; TABLET DISINTEGRATION; TREATMENT OUTCOME; URINALYSIS;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DRUGS, GENERIC; HUMANS; OSTEOPOROSIS; SOUTH AFRICA;

EID: 33748350468     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443.
2. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial (FIT). J Clin Endocrinol Metab 2000; 85: 4118-4124
3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled study (VERT). JAMA 1999; 282: 1344-1352.
4. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-340.
5. Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986, 24: 57-62.
6. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review Drug Saf 1996; 14: 158-170.
7. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-1021.
8. Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 2000; 95: 634-640.
9. Lanza FL, Hunt RH, Thompson AB, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 631-638.
10. Chesnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic women: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99:144-152.
11. McClung M, Clemmesen B, Daifotis A. Alendronate prevents bone loss in women without osteoporosis: A double-blind, randomized, controlled trial. Ann Intern Med 1998; 128: 253-261.
12. Agrawal S, Kreuger DC, Engelke JA, et al. Between-meal risedromate does not alter bone turnover in nursing home residents. J Am Geriatr Soc 2006; 54: 790-795.
13. Tankó LB, McClung MR, Schimmer RC. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 2003; 32: 421-426.
14. Ott SM, Woodson GC, Huffer WE, Miller PD, Watts NB. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 78: 968-972.
15. Conte PF, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. The Oncologist 2004; 9(4): 28-37.
16. Cooper C, Emkey RD, McDonald RH, et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 4609-4615.
17. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-1301.
18. Ruggiero SL, Mebrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaw associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 27-34.
19. Epstein S, Cryer B, Ragi S, et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2003; 19: 781-789.
20. Epstein S, Geusens P, Fisher JE, et al. Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy. Journal of Applied Research 2005; 5: 253-265.